These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 15924505)

  • 1. Dose adjustment in patients with liver disease.
    Delcò F; Tchambaz L; Schlienger R; Drewe J; Krähenbühl S
    Drug Saf; 2005; 28(6):529-45. PubMed ID: 15924505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
    Verbeeck RK
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1147-61. PubMed ID: 18762933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.
    Schlatter C; Egger SS; Tchambaz L; Krähenbühl S
    Drug Saf; 2009; 32(7):561-78. PubMed ID: 19530743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluctuation of the renal function after discharge from hospital and its effects on drug dosing in elderly patients--study protocol.
    Eppenga WL; Wester WN; Derijks HJ; Hoedemakers RM; Wensing M; De Smet PA; Van Marum RJ
    BMC Nephrol; 2015 Jul; 16():95. PubMed ID: 26149449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.
    Morgan DJ; McLean AJ
    Clin Pharmacokinet; 1995 Nov; 29(5):370-91. PubMed ID: 8582120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of melatonin in man: first pass hepatic metabolism.
    Lane EA; Moss HB
    J Clin Endocrinol Metab; 1985 Dec; 61(6):1214-6. PubMed ID: 4055987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose adaptation of antineoplastic drugs in patients with liver disease.
    Tchambaz L; Schlatter C; Jakob M; Krähenbühl A; Wolf P; Krähenbühl S
    Drug Saf; 2006; 29(6):509-22. PubMed ID: 16752933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug dosing in chronic hepatic disease (author's transl)].
    Gugler R; Eichelbaum M
    Leber Magen Darm; 1981 Apr; 11(2):81-7. PubMed ID: 7015045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis.
    Assy N; Kayal M; Mejirisky Y; Gorenberg M; Hussein O; Schlesinger S
    BMC Gastroenterol; 2006 Nov; 6():39. PubMed ID: 17134488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered hepatic blood flow and drug disposition.
    Nies AS; Shand DG; Wilkinson GR
    Clin Pharmacokinet; 1976; 1(2):135-55. PubMed ID: 13954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug administration in chronic liver disease.
    Westphal JF; Brogard JM
    Drug Saf; 1997 Jul; 17(1):47-73. PubMed ID: 9258630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mechanism of action of xipamide and its classification as a "low ceiling diuretic". Pharmacodynamic-pharmacokinetic studies in healthy volunteers and in kidney and liver patients].
    Knauf H; Mutschler E
    Arzneimittelforschung; 2005; 55(1):1-14. PubMed ID: 15727159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmics: elimination and dosage considerations in hepatic impairment.
    Klotz U
    Clin Pharmacokinet; 2007; 46(12):985-96. PubMed ID: 18027986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered disposition and availability of cimetidine in liver cirrhotic patients.
    Gugler R; Müller-Liebenau B; Somogyi A
    Br J Clin Pharmacol; 1982 Sep; 14(3):421-30. PubMed ID: 7126415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of ampicillin in cirrhosis.
    Lewis GP; Jusko WJ
    Clin Pharmacol Ther; 1975 Oct; 18(4):475-84. PubMed ID: 1164828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs.
    Yuan R; Venitz J
    Int J Clin Pharmacol Ther; 2000 May; 38(5):245-53. PubMed ID: 10839468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.
    Steelandt J; Jean-Bart E; Goutelle S; Tod M
    Clin Pharmacokinet; 2015 Dec; 54(12):1245-58. PubMed ID: 26070946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy of ascites associated with cirrhosis.
    Ginès P; Arrovo V; Rodés J
    Drugs; 1992 Mar; 43(3):316-32. PubMed ID: 1374317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of urea synthesis by diet protein and carbohydrate in normal man and in patients with cirrhosis. Relationship to glucagon and insulin.
    Hamberg O
    Dan Med Bull; 1997 Jun; 44(3):225-41. PubMed ID: 9233544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Individualization of drug therapy in renal or liver insufficiency].
    Martin-Facklam M
    Ther Umsch; 2000 Sep; 57(9):568-72. PubMed ID: 11036437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.